Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 230 participants.
Also called NCT07076056
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 230 participants
- Registry
-
NCT07076056
-
- Other papers using this trial's data
- Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT07076056. Randomized; double masking; primary purpose treatment. Start 2022-10-27 (actual); primary completion 2023-12-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- DW1026C1
- Intervention (Drug)
- DW1026C2
- Intervention (Drug)
- DW1026S
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07076056- Content hash
109f7cfeee0d27d36444d4f81ed55c4a993d57f174b167ea8be3944d535a479b